View details of this raise on Seedstage

Kalamazoo, MI

Developing a home-based system for diabetic foot ulcer treatment.

• Innovative Treatment: SenLore combines electrical stimulation and thermal therapy for home-based DFU treatment.
• High Healing Rate: Achieves up to a 70% healing rate, nearly triple the industry standard.
• Cost Savings: Prevents complications, saving $17,000 per patient annually.
• Patented Technology: Protected by a multi-jurisdictional patent portfolio.
• Market Potential: Targets the $15B DFU crisis with a scalable, high-ROI solution.

Adlore is transitioning from research and development to market commercialization with its flagship system, SenLore. This system employs a patented dual-action approach that combines electrical stimulation and thermal therapy to treat diabetic foot ulcers (DFUs) at home. The company aims to scale this solution to address the needs of the 37 million Americans living with diabetes, as well as other wounds and pathologies with decreased blood flow.

Adlore envisions a future where a diabetic diagnosis does not lead to limb loss. The SenLore system features non-adhesive insole electrodes and a unique stimulation pattern that boosts blood flow, achieving up to a 70% healing rate. This approach not only treats ulcers but also restores independence, particularly benefiting rural communities and people of color who face higher amputation rates. By bridging healthcare gaps and reducing recurrence rates, Adlore aims to transform chronic wound care into a scalable ecosystem.

Company Info

Adlore develops the SenLore system to enhance diabetic foot ulcer treatment through home-based clinical-grade technology.

Adlore focuses on improving the treatment of diabetic foot ulcers (DFUs) by transitioning clinical-grade wound healing technology from hospitals to homes. Their flagship product, SenLore, utilizes a patented dual-action approach that combines electrical stimulation and thermal therapy to enhance healing efficiency. This system is designed to address the needs of the 37 million Americans living with diabetes, particularly those in rural areas and communities of color who face higher amputation rates due to healthcare disparities.

The SenLore system features non-adhesive insole electrodes and a unique ‘whirlpool’ electrical stimulation pattern, which significantly boosts blood flow and healing rates. By integrating Remote Patient Monitoring (RPM), Adlore aims to reduce recurrence rates and healthcare costs, offering a scalable solution to the $15 billion DFU crisis. Their business model leverages existing reimbursement codes to align clinician incentives with patient outcomes, positioning Adlore as a key player in the limb-preservation market.